{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/08/06/3340187/0/en/Theriva-Biologics-Announces-First-Patient-Dosed-in-VIRAGE2-Phase-2a-Clinical-Trial-to-Evaluate-More-Frequent-Dosing-of-VCN-01-zabilugene-almadenorepvec-in-First-Line-Patients-with-.html", "message": "News view counter 868107 successfully enlarged"}